Sanofi Defends Lyxumia Under Scrutiny at Diabetes Meeting
This article is for subscribers only.
Sanofi defended its experimental drug Lyxumia after some scientists questioned the medicine’s novelty at a diabetes conference.
Lyxumia isn’t “at all” an imitation of Bristol-Myers Squibb Co.’s Byetta, Pierre Chancel, who heads Sanofi Diabetes, said yesterday in Berlin, where he attended the European Association for the Study of Diabetes conference. The drug is “as effective as Byetta with one injection a day, super simple to use and super safe,” he said in an interview.